Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
NCT02201849 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults
- Lead sponsor
- Biogen
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 31, 2014
- Completion date
- December 31, 2014
- Enrollment
- 104 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.